top of page
Search
Biologics R&D: select news
Innovative approach for the clinical development of a Chlamydia trachomatis vaccine through a human challenge model in women
https://pubmed.ncbi.nlm.nih.gov/40032135/
jeanfrancoismaison
Apr 211 min read
A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models
https://pubmed.ncbi.nlm.nih.gov/40254611/
jeanfrancoismaison
Apr 211 min read
Bioinspired Membrane-Based Cancer Vaccines for Immunotherapy: Progress and Perspectives
https://pubmed.ncbi.nlm.nih.gov/40255117/
jeanfrancoismaison
Apr 211 min read
Repertoire-based mapping and time-tracking of T helper cell subsets in scRNA-Seq
https://pubmed.ncbi.nlm.nih.gov/40255395/
jeanfrancoismaison
Apr 211 min read
Incorporating vaccines into vaccination schedules around the world: A scoping review
https://pubmed.ncbi.nlm.nih.gov/40250066/
jeanfrancoismaison
Apr 201 min read
Incorporating vaccines into vaccination schedules around the world: A scoping review
https://pubmed.ncbi.nlm.nih.gov/40250066/
jeanfrancoismaison
Apr 201 min read
Safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis
https://pubmed.ncbi.nlm.nih.gov/40251607/
jeanfrancoismaison
Apr 201 min read
The therapeutic effect of mRNA vaccines in glioma: a comprehensive review
https://pubmed.ncbi.nlm.nih.gov/40249391/
jeanfrancoismaison
Apr 201 min read
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial
https://pubmed.ncbi.nlm.nih.gov/40158524/
jeanfrancoismaison
Apr 201 min read
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial
https://pubmed.ncbi.nlm.nih.gov/40158526/
jeanfrancoismaison
Apr 201 min read
Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014-2022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic
https://pubmed.ncbi.nlm.nih.gov/40252365/
jeanfrancoismaison
Apr 201 min read
The validity of test-negative design for assessment of typhoid conjugate vaccine protection: comparison of estimates by different study designs using data from a cluster-randomised controlled trial
https://pubmed.ncbi.nlm.nih.gov/40252689/
jeanfrancoismaison
Apr 201 min read
Finalising the WHO Pandemic Agreement for a safer future
https://pubmed.ncbi.nlm.nih.gov/40253094/
jeanfrancoismaison
Apr 201 min read
Scientific and Regulatory Policy Committee Points to Consider: Proposal and Recommendations to Reduce Euthanasia of Control Nonhuman Primates in Nonclinical Toxicity Studies
https://pubmed.ncbi.nlm.nih.gov/39881485/
jeanfrancoismaison
Apr 201 min read
Group A Streptococcus Vaccine Development: An Indian Public Health Imperative
https://pubmed.ncbi.nlm.nih.gov/40252837/
jeanfrancoismaison
Apr 201 min read
Harnessing cytokine immunocomplexes and cytokine fusion proteins for cancer Therapy: Mechanisms and clinical potential
https://pubmed.ncbi.nlm.nih.gov/40233680/
jeanfrancoismaison
Apr 161 min read
γδT cells, a key subset of T cell for cancer immunotherapy
https://pubmed.ncbi.nlm.nih.gov/40226616/
jeanfrancoismaison
Apr 151 min read
From Bench to Bedside: Translational Approaches to Cardiotoxicity in Breast Cancer, Lung Cancer, and Lymphoma Therapies
https://pubmed.ncbi.nlm.nih.gov/40227572/
jeanfrancoismaison
Apr 151 min read
Immunological Tolerance to Luciferase and Fluorescent Proteins using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
https://pubmed.ncbi.nlm.nih.gov/40228139/
jeanfrancoismaison
Apr 151 min read
Considerations from the pharmaceutical industry (IQ MPS affiliate) workshop on animal microphysiological systems and 3Rs in drug development
https://pubmed.ncbi.nlm.nih.gov/40219861/
jeanfrancoismaison
Apr 141 min read
bottom of page